title: Pneumococcal transmission and disease in silico: a microsimulation model of the indirect effects of vaccination.
abstract: BACKGROUND
  The degree and time frame of indirect effects of vaccination (serotype replacement and herd immunity) are key determinants in assessing the net effectiveness of vaccination with pneumococcal conjugate vaccines (PCV) in control of pneumococcal disease. Using modelling, we aimed to quantify these effects and their dependence on coverage of vaccination and the vaccine's efficacy against susceptibility to pneumococcal carriage.
  
  
  RESULTS
  We constructed an individual-based simulation model that explores the effects of large-scale PCV programmes and applied it in a developed country setting (Finland). A population structure with transmission of carriage taking place within relevant mixing groups (families, day care groups, schools and neighbourhoods) was considered in order to properly assess the dependency of herd immunity on coverage of vaccination and vaccine efficacy against carriage. Issues regarding potential serotype replacement were addressed by employing a novel competition structure between multiple pneumococcal serotypes. Model parameters were calibrated from pre-vaccination data about the age-specific carriage prevalence and serotype distribution. The model predicts that elimination of vaccine-type carriage and disease among those vaccinated and, due to a substantial herd effect, also among the general population takes place within 5-10 years since the onset of a PCV programme with high (90%) coverage of vaccination and moderate (50%) vaccine efficacy against acquisition of carriage. A near-complete replacement of vaccine-type carriage by non-vaccine-type carriage occurs within the same time frame.
  
  
  CONCLUSIONS
  The changed patterns in pneumococcal carriage after PCV vaccination predicted by the model are unequivocal. The overall effect on disease incidence depends crucially on the magnitude of age- and serotype-specific case-to-carrier ratios of the remaining serotypes relative to those of the vaccine types. Thus the availability of reliable data on the incidence of both pneumococcal carriage and disease is essential in assessing the net effectiveness of PCV vaccination in a given epidemiological setting.
authors: Department of Vaccination and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland. markku.nurhonen@thl.fi
authors: Markku
authors: M
authors: Nurhonen
authors: Allen C
authors: AC
authors: Cheng
authors: Kari
authors: K
authors: Auranen
mesh_terms: D000293:Adolescent; D000367:Age Factors; D002353:Carrier State / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control / Q000635:transmission; D002648:Child; D002675:Child, Preschool; D003198:Computer Simulation; D005387:Finland / Q000453:epidemiology; D006801:Humans; D032521:Immunity, Herd; D007223:Infant; D008954:Models, Biological; D018803:Models, Economic; D011008:Pneumococcal Infections / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission*; D022242:Pneumococcal Vaccines / Q000191:economics* / Q000627:therapeutic use*; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification / Q000472:pathogenicity*; D014611:Vaccination / Q000191:economics
chemical_list: D022242:Pneumococcal Vaccines